Business Description
MAIA Biotechnology Inc
NAICS : 325412
SIC : 2834
ISIN : US5526411021
Total Employee Number:
13Description
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.79 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 25.7 | |||||
3-Year EPS without NRI Growth Rate | 25.2 | |||||
3-Year FCF Growth Rate | 23.4 | |||||
3-Year Book Growth Rate | -56.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.56 | |||||
9-Day RSI | 54.49 | |||||
14-Day RSI | 54.72 | |||||
3-1 Month Momentum % | -5.11 | |||||
6-1 Month Momentum % | -21.21 | |||||
12-1 Month Momentum % | -26.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.59 | |||||
Quick Ratio | 5.59 | |||||
Cash Ratio | 5.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.2 | |||||
Shareholder Yield % | -51.36 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -310.88 | |||||
ROA % | -152.09 | |||||
ROIC % | -2303.11 | |||||
3-Year ROIIC % | 7589.62 | |||||
ROCE % | -257.38 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.14 | |||||
Price-to-Tangible-Book | 3.13 | |||||
EV-to-EBIT | -2.17 | |||||
EV-to-Forward-EBIT | -1.63 | |||||
EV-to-EBITDA | -2.17 | |||||
EV-to-Forward-EBITDA | -1.6 | |||||
EV-to-Forward-Revenue | 0.69 | |||||
EV-to-FCF | -2.66 | |||||
| Price-to-Net-Current-Asset-Value | 3.13 | |||||
| Price-to-Net-Cash | 3.27 | |||||
Earnings Yield (Greenblatt) % | -46.08 | |||||
FCF Yield % | -22.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:MAIA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MAIA Biotechnology Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.67 | ||
| Beta | -0.8664 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.42 | ||
| Volatility % | 82.89 | ||
| 14-Day RSI | 54.72 | ||
| 14-Day ATR ($) | 0.089578 | ||
| 20-Day SMA ($) | 1.4135 | ||
| 12-1 Month Momentum % | -26.97 | ||
| 52-Week Range ($) | 0.87 - 3.19 | ||
| Shares Outstanding (Mil) | 60.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MAIA Biotechnology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MAIA Biotechnology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 114 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 27 days | ||
| General meeting for 2026 | 2026-05-21 10:00 | 1.29 (+1.57%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.32 (+1.54%) | ||
| Annual report for 2025 | 2026-03-23 | 1.46 (-1.22%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 1.10 (-1.79%) | ||
| Second quarter earnings results for 2025 | 2025-08-11 | 1.52 (+3.40%) | ||
| General meeting for 2025 | 2025-05-22 10:00 | 1.74 (-4.92%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 1.96 (-1.01%) | ||
| Guidance call for 2025 | 2025-03-28 12:00 | 1.63 (+0.62%) |
Show
Entries
MAIA Biotechnology Inc Frequently Asked Questions
What is MAIA Biotechnology Inc(MAIA)'s stock price today?
The current price of MAIA is $1.44. The 52 week high of MAIA is $3.19 and 52 week low is $0.87.
When is next earnings date of MAIA Biotechnology Inc(MAIA)?
The next earnings date of MAIA Biotechnology Inc(MAIA) is 2026-08-11 Est..
Does MAIA Biotechnology Inc(MAIA) pay dividends? If so, how much?
MAIA Biotechnology Inc(MAIA) does not pay dividend.
Guru Commentaries on AMEX:MAIA
No articles.
Press Release
Articles on MAIA Biotechnology Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers